Lipocine’s (LPCN) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Lipocine (NASDAQ:LPCN) in a report released on Monday, Marketbeat.com reports. The brokerage currently has a $4.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for Lipocine’s Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.54) EPS and FY2027 earnings at ($1.03) EPS.

A number of other equities analysts also recently commented on the stock. Weiss Ratings downgraded shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Lipocine presently has an average rating of “Hold” and a consensus price target of $4.00.

Lipocine Stock Performance

NASDAQ LPCN opened at $2.12 on Monday. The company has a market capitalization of $17.47 million, a price-to-earnings ratio of -1.19 and a beta of 0.47. The company’s 50-day simple moving average is $2.18 and its two-hundred day simple moving average is $2.99. Lipocine has a one year low of $1.81 and a one year high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million. Equities analysts expect that Lipocine will post -1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Lipocine by 57.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after purchasing an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Lipocine in the 1st quarter worth $185,000. Exome Asset Management LLC purchased a new position in Lipocine during the 1st quarter worth $486,000. Persistent Asset Partners Ltd purchased a new position in Lipocine during the 4th quarter worth $567,000. Finally, Seven Fleet Capital Management LP acquired a new position in Lipocine during the 1st quarter valued at about $998,000. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.